{"id":"cefetamet","rwe":[],"tags":[{"label":"cefetamet","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01DD10","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"deacetoxycefotaxime","offLabel":[],"synonyms":["cefetamet","deacetoxycefotaxime"],"timeline":[],"brandName":"Deacetoxycefotaxime","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"cefetamet","explanation":"Imagine your body's cells are like buildings with walls. Bacteria have special machines that build these walls, and deacetoxycefotaxime blocks these machines, causing the walls to collapse and the bacteria to die.","oneSentence":"Deacetoxycefotaxime works by inhibiting the bacterial enzyme responsible for cell wall synthesis, ultimately leading to cell lysis and death.","technicalDetail":"Deacetoxycefotaxime exerts its antibacterial effect by competitively inhibiting the transpeptidase enzyme, which is essential for the cross-linking of peptidoglycan chains in the bacterial cell wall, ultimately leading to cell lysis and death."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3074","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CEFETAMET","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEFETAMET","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:13:20.065826","biosimilars":[],"competitors":[{"drugName":"cefotaxime","drugSlug":"cefotaxime","fdaApproval":"1981-03-11","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ceftazidime","drugSlug":"ceftazidime","fdaApproval":"1985-07-19","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ceftriaxone","drugSlug":"ceftriaxone","fdaApproval":"1984-12-21","genericCount":26,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefmenoxime","drugSlug":"cefmenoxime","fdaApproval":"1987-12-30","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"latamoxef","drugSlug":"latamoxef","fdaApproval":"","relationship":"same-class"},{"drugName":"ceftizoxime","drugSlug":"ceftizoxime","fdaApproval":"1983-09-15","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefixime","drugSlug":"cefixime","fdaApproval":"1989-04-28","patentExpiry":"Dec 14, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"cefpiramide","drugSlug":"cefpiramide","fdaApproval":"1989-01-31","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"cefoperazone","drugSlug":"cefoperazone","fdaApproval":"1982-11-18","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefpodoxime proxetil","drugSlug":"cefpodoxime-proxetil","fdaApproval":"1992-08-07","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ceftibuten","drugSlug":"ceftibuten","fdaApproval":"1995-12-20","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"cefdinir","drugSlug":"cefdinir","fdaApproval":"1997-12-04","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefditoren pivoxil","drugSlug":"cefditoren-pivoxil","fdaApproval":"2001-08-29","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"cefetamet","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cefotaxime","brandName":"cefotaxime","genericName":"cefotaxime","approvalYear":"1981","relationship":"same-class"},{"drugId":"ceftazidime","brandName":"ceftazidime","genericName":"ceftazidime","approvalYear":"1985","relationship":"same-class"},{"drugId":"ceftriaxone","brandName":"ceftriaxone","genericName":"ceftriaxone","approvalYear":"1984","relationship":"same-class"},{"drugId":"cefmenoxime","brandName":"cefmenoxime","genericName":"cefmenoxime","approvalYear":"1987","relationship":"same-class"},{"drugId":"latamoxef","brandName":"latamoxef","genericName":"latamoxef","approvalYear":"","relationship":"same-class"},{"drugId":"ceftizoxime","brandName":"ceftizoxime","genericName":"ceftizoxime","approvalYear":"1983","relationship":"same-class"},{"drugId":"cefixime","brandName":"cefixime","genericName":"cefixime","approvalYear":"1989","relationship":"same-class"},{"drugId":"cefpiramide","brandName":"cefpiramide","genericName":"cefpiramide","approvalYear":"1989","relationship":"same-class"},{"drugId":"cefoperazone","brandName":"cefoperazone","genericName":"cefoperazone","approvalYear":"1982","relationship":"same-class"},{"drugId":"cefpodoxime-proxetil","brandName":"cefpodoxime proxetil","genericName":"cefpodoxime proxetil","approvalYear":"1992","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04664803","phase":"PHASE4","title":"Safety and Efficacy of Cefecin Tab. in Patients With Acute Sinusitis","status":"TERMINATED","sponsor":"Korea United Pharm. Inc.","startDate":"2015-08-31","conditions":["Acute Sinusitis"],"enrollment":284,"completionDate":"2019-08-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"006034","UNII":"4R5TV783X3","CHEBI":"CHEBI:135629","INN_ID":"5330","RXNORM":"20482","UMLSCUI":"C1148061","ChEMBL_ID":"CHEMBL2103764","KEGG_DRUG":"D03424","DRUGBANK_ID":"DB13504","PUBCHEM_CID":"5487888","SNOMEDCT_US":"443045001","IUPHAR_LIGAND_ID":"12416","MESH_SUPPLEMENTAL_RECORD_UI":"C047444"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.1 hours","clearance":"1.9 mL/min/kg","bioavailability":"47%","fractionUnbound":"0.78%","volumeOfDistribution":"0.28 L/kg"},"publicationCount":167,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J01DD10","allCodes":["J01DD10"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Deacetoxycefotaxime, also known as CEFETAMET, is a third-generation cephalosporin antibiotic belonging to the cefetamet drug class. It is a small molecule modality, but its current commercial status and approved indications are unknown. The pharmacokinetic properties of CEFETAMET include a half-life of 2.1 hours and bioavailability of 47%. As a cephalosporin antibiotic, it works by inhibiting bacterial cell wall synthesis, but its specific target is unknown. Further research is needed to determine its clinical utility and safety profile.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}